ArticleEuropean radiology2026
Single and multi-site CT-based radiogenomics analysis of metastatic lung adenocarcinoma and correlations with outcome.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRadiogenomic studies have mostly linked single-site radiomic features (RFs) to genomic alterations in locally-advanced lung cancer, limiting their applicability to patients with metastatic lung adenocarcinoma (MLUAD). Our aim was to evaluate associations between unsupervised CT-based radiomic clustering of single-site and multi-site features and oncogenic alterations (OAs) and response to treatment in MLUAD. MATERIALS AND
methodsPatients managed at our center (October 2016-January 2024) with pre-treatment CT scans and next-generation sequencing were retrospectively included. Reproducible RFs were extracted from all solid tumor lesions > 1 cm³ using an automated pipeline. Patient-level integration used the centroid of each patient's lesions in radiomic space, providing multi-site radiomics data. RFs from the largest and biopsied lesions were also isolated. Patients were clustered by unsupervised hierarchical consensus clustering using centroid-based (Cluster-C), largest lesion (Cluster-M), and biopsied lesion (Cluster-B) features. Uni- and multivariable associations with OAs (any OA, smoker-related [sOA], non-smoker-related [nsOA], or wild-type), overall response rate (ORR), and overall survival (OS) were investigated.
resultsAmong 361 patients (median age 63.2 years; 41.3% women; 1721 segmented tumor lesions), 48.2% had sOA and 13% had nsOA. Cluster-M2 + M5 was enriched in KRAS (p = 0.048), MET (p = 0.046), and PI3KCA (p < 0.001) alterations. Cluster-M (especially Cluster-M2 + M5) independently predicted sOA (OR = 2.28, p = 0.006), and nsOA (OR = 5.49, p = 0.004). Cluster-M was linked to higher ORR (p = 0.026) and longer OS (p = 0.016).
conclusionBaseline CT-based single- and multi-site radiomics capture patterns associated with key OAs in MLUAD, suggesting their potential role as a non-invasive adjunct to guide molecular testing and optimize treatment selection. KEY POINTS: Question In MLUAD, can single- and multi-site RFs from all measurable lesions enhance the detection of key OAs and outcome prediction beyond standard clinical-radiological assessment? Findings In 361 MLUAD patients, robust clustering using RFs from multiple tumor lesions per patient identified subgroups associated with key OAs, response to treatment, and survival. Clinical relevance Whatever the initial disease staging, radiomic clustering may serve as a non-invasive AI biomarker that complements molecular testing, helping identify actionable tumor profiles and stratify patients for treatment selection and prognostication in MLUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.